In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Fintel reports that on December 31, 2024, DA Davidson initiated coverage of Vertex (NasdaqGM:VERX) with a Buy recommendation.

Vertex (VERX) has received a new Buy rating, initiated by D.A. Davidson analyst, Will Jellison.Don't Miss Our New Year's Offers:Discover the ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...